All Blogs

Jul 27, 2022

Around 50 million people in the United States live with—and suffer from—chronic pain. The prevalence of chronic pain has grown significantly over the past few decades due to lifestyle changes, traumatic injury, a rise in critical surgeries, and growth in the overweight or obese population, among serval other underl...

Jul 26, 2022

FDA Approves Incyte’s Opzelura as First Vitiligo Therapy The US Food and Drug Administration has approved Incyte’s Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older. With this approval, Opzelura is the first and only FDA-approved...

Jul 25, 2022

Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of low-weight or premature infants, with the risk of development proportional to the degree of prematurity. It is also referred to as chronic lung disease of premature babies. It is a chronic respiratory disease that often occurs in low-w...

Jul 22, 2022

Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landscape changed the market once dominated by Roche.Moving forward, RVO’s robust pipeline, along with several VEGF inhibitors, creates trouble for the big ones; Lucentis and Eylea. Retinal vein occlusion is the second most common s...

Jul 21, 2022

Orthox Obtains MHRA Approval to Commence FFLEX Study  On July 14, 2022, Orthodox Ltd, a clinical-stage company created medical implants to treat orthopedic problems including damaged knee articular cartilage. It was founded in 2008 by life scientist, Dr. Nick Skaer, and knee surgeon, Professor Oliver Kessle...

Jul 06, 2025

Nanobots in medicine and healthcare represent one of the most promising frontiers in modern science, poised to revolutionize diagnosis, treatment, and patient monitoring at a molecular level. These microscopic machines, often referred to as nanobots, nanorobots, or medical nanobots, are engineered to operate within...

Jul 19, 2022

Byondis Files its HER2-Targeting Antibody-Drug Conjugate (ADC) Trastuzumab Duocarmazine in the US and Europe Byondis has filed for clearance of its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the United States and Europe, setting up a battle with heavyweight competitors Roche and Ast...

Jul 18, 2022

Wilson’s disease is a rare genetic disorder caused by mutations in the P-type ATPase gene. Wilson’s disease causes defective biliary excretion of copper, leading to its accumulation, particularly in the liver and brain. The ATP7B gene is responsible for the transportation of copper from the liver to the intestine t...

Jul 15, 2022

Burn is a global public health problem, causing more than 180,000 deaths per year across the world. The vast majority of these occur in low- and middle-income nations. Moreover, non-fatal burns are a primary source of morbidity, resulting in lengthy hospitalization, deformity, and disability, as well as stigma and ...

Jul 14, 2022

Zsquare ENT-Flex™ Rhinolaryngoscope, the First High-Performance Single-Use ENT Endoscope of Zsquare received FDA Clearance On July 06, 2022, Zsquare, one of the leading developers of high-performance, single-use endoscopes, received Food and Drug Administration 510K clearance to market its first product, the Zsq...